2011
DOI: 10.1002/mus.22096
|View full text |Cite
|
Sign up to set email alerts
|

Myasthenia gravis exacerbation after cetirizine administration

Abstract: Background Although perhaps the most common worker‐management structure, there has been surprisingly little research on describing and evaluating the characteristics of health and safety committees. Methods A survey of 380 health and safety committee members from 176 manufacturing workplaces was supplemented with administrative data and compared with reported workers' compensation rates. Survey respondents also reported perceptions of overall safety, committee, effectiveness, committee activities, and “best pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…In other words, while they may cause antimuscarinic effects (e.g., dry mouth, blurry vision, constipation, urinary retention, drowsiness), they should not theoretically produce antinicotinic effects (e.g., neuromuscular blockade or skeletal muscle weakness) the latter would be particularly problematic in myasthenia gravis (16). However, in one case it was reported that cetirizine appeared to trigger an episode of diplopia, dysphagia, and facial weakness in a patient with a history of myasthenia gravis previously in complete stable remission; the mechanism by which this likely occurred is unclear but may be related to the anticholinergic properties of the disease (17).…”
Section: Pharmacologic Considerations In Myasthenia Gravis and Overvimentioning
confidence: 99%
“…In other words, while they may cause antimuscarinic effects (e.g., dry mouth, blurry vision, constipation, urinary retention, drowsiness), they should not theoretically produce antinicotinic effects (e.g., neuromuscular blockade or skeletal muscle weakness) the latter would be particularly problematic in myasthenia gravis (16). However, in one case it was reported that cetirizine appeared to trigger an episode of diplopia, dysphagia, and facial weakness in a patient with a history of myasthenia gravis previously in complete stable remission; the mechanism by which this likely occurred is unclear but may be related to the anticholinergic properties of the disease (17).…”
Section: Pharmacologic Considerations In Myasthenia Gravis and Overvimentioning
confidence: 99%